Nightstar
Acquired
- Headquarters
- Oxford
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- nightstartx.com
- Total Funding
- $99.1M
- Last Round
- $45.0M Series CJun 2017
About
Nightstar Therapeutics was an Oxford University spinout developing adeno-associated virus (AAV) gene therapies for inherited retinal diseases including choroideremia and retinitis pigmentosa. Founded in 2014, it completed a NASDAQ IPO in 2017 and was acquired by Biogen for approximately $800 million in June 2019.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account